Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Jiangsu Simcere Pharmaceutical Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising antibody or antigen-binding fragments linked to a cytotoxic drug through a linker reported to be useful for the treatment of atopic dermatitis.

Haisco Pharmaceutical Group Co. Ltd. has synthesized G protein-coupled receptor GPR52 agonists reported to be useful for the treatment of psychiatric disorders.

Innolake Biopharm (Hangzhou) Co. Ltd. has disclosed antibody-drug conjugates comprising bispecific antibodies covalently bound to exatecan through a linker reported to be useful for the treatment of cancer.

Convergen (Suzhou) Pharmaceutical Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a serine/threonine-protein kinase PAK4-targeting moiety through a linker reported to be useful for the treatment of cancer.

Jiangsu Carephar Pharmaceutical Co. Ltd. has divulged angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.

Guangzhou Runer Ophthalmic Biotechnology Co. Ltd. has identified complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, asthma, atherosclerosis, Crohn’s disease, glomerular disorders, hemolytic uremic syndrome, neurological disorders and diabetic retinopathy, among others.

Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Hainan Simcere Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising a glycoengineered antibody covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Huayao Jiyuan (Shenzhen) Pharmaceutical Co. Ltd. has described hypoxia inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of cancer, infections, cardiovascular disorders, anemia, chronic kidney disease, disorders of hematopoiesis, inflammatory disorders and acute respiratory distress syndrome (ARDS).